Alan J Thompson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4470751/publications.pdf

Version: 2024-02-01

302 papers	54,467 citations	3515 90 h-index	1250 226 g-index
320 all docs	320 docs citations	320 times ranked	31369 citing authors

#	Article	IF	Citations
1	Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of Neurology, 2011, 69, 292-302.	2.8	8,001
2	Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Annals of Neurology, 2001, 50, 121-127.	2.8	6,122
3	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, The, 2018, 17, 162-173.	4.9	4,605
4	Diagnostic criteria for multiple sclerosis: 2005 revisions to the â€œMcDonald Criteriaâ€: Annals of Neurology, 2005, 58, 840-846.	2.8	4,495
5	Defining the clinical course of multiple sclerosis. Neurology, 2014, 83, 278-286.	1.5	2,344
6	Multiple sclerosis. Lancet, The, 2018, 391, 1622-1636.	6.3	1,204
7	Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology, 2014, 83, 1022-1024.	1.5	953
8	The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure. Brain, 2001, 124, 962-973.	3.7	865
9	A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis. New England Journal of Medicine, 2002, 346, 158-164.	13.9	806
10	Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain, 2008, 131, 808-817.	3.7	783
11	Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS) Tj ETQq1 1 0.784314 rgBT /Overlo	6.3	729
12	Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurology, The, 2012, 11, 150-156.	4.9	548
13	Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain, 2002, 125, 1676-1695.	3.7	534
14	Functionalâ€“Anatomical Validation and Individual Variation of Diffusion Tractography-based Segmentation of the Human Thalamus. Cerebral Cortex, 2005, 15, 31-39.	1.6	514
15	Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurology, The, 2005, 4, 281-288.	4.9	513
16	Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Annals of Neurology, 1991, 29, 53-62.	2.8	488
17	Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Annals of Neurology, 2005, 58, 383-391.	2.8	477
18	New insights into the burden and costs of multiple sclerosis in Europe. Multiple Sclerosis Journal, 2017, 23, 1123-1136.	1.4	472

#	Article	IF	Citations
19	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 96-120.	1.4	458
20	Gray matter atrophy is related to longâ€term disability in multiple sclerosis. Annals of Neurology, 2008, 64, 247-254.	2.8	425
21	Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurology, The, 2007, 6, 1094-1105.	4.9	412
22	Motor system activation after subcortical stroke depends on corticospinal system integrity. Brain, 2006, 129, 809-819.	3.7	369
23	Diffusion-based tractography in neurological disorders: concepts, applications, and future developments. Lancet Neurology, The, 2008, 7, 715-727.	4.9	360
24	Recommendations from the national multiple sclerosis society clinical outcomes assessment task force. Annals of Neurology, 1997, 42, 379-382.	2.8	342
25	Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain, 2004, 127, 1101-1107.	3.7	335
26	Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain, 2003, 126, 2191-2202.	3.7	330
27	Exercise in patients with multiple sclerosis. Lancet Neurology, The, 2017, 16, 848-856.	4.9	316
28	MRI in multiple sclerosis: current status and future prospects. Lancet Neurology, The, 2008, 7, 615-625.	4.9	295
29	Deep gray matter volume loss drives disability worsening in multiple sclerosis. Annals of Neurology, 2018, 83, 210-222.	2.8	295
30	MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurology, The, 2007, 6, 677-686.	4.9	292
31	Progression of regional grey matter atrophy in multiple sclerosis. Brain, 2018, 141, 1665-1677.	3.7	269
32	Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain, 2000, 123, 1027-1040.	3.7	265
33	The Evolution of Prefrontal Inputs to the Cortico-pontine System: Diffusion Imaging Evidence from Macaque Monkeys and Humans. Cerebral Cortex, 2006, 16, 811-818.	1.6	258
34	Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Annals of Neurology, 2002, 52, 47-53.	2.8	251
35	MRI investigation of the sensorimotor cortex and the corticospinal tract after acute spinal cord injury: a prospective longitudinal study. Lancet Neurology, The, 2013, 12, 873-881.	4.9	239
36	Disability, atrophy and cortical reorganization following spinal cord injury. Brain, 2011, 134, 1610-1622.	3.7	238

#	Article	IF	Citations
37	Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet, The, 2017, 389, 1357-1366.	6.3	235
38	From diffusion tractography to quantitative white matter tract measures: a reproducibility study. NeuroImage, 2003, 18, 348-359.	2.1	219
39	Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. Journal of Neurology, 2003, 250, 1407-1419.	1.8	216
40	Spinal-cord MRI in multiple sclerosis. Lancet Neurology, The, 2003, 2, 555-562.	4.9	213
41	Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain, 2004, 127, 1361-1369.	3.7	193
42	Functional anatomy of interhemispheric cortical connections in the human brain. Journal of Anatomy, 2006, 209, 311-320.	0.9	192
43	Treatment of cognitive impairment in multiple sclerosis: position paper. Journal of Neurology, 2013, 260, 1452-1468.	1.8	189
44	Probabilistic diffusion tractography: a potential tool to assess the rate of disease progression in amyotrophic lateral sclerosis. Brain, 2006, 129, 1859-1871.	3.7	177
45	Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: Evidence that axonal loss is a substrate of MRI-detected atrophy. NeuroImage, 2006, 31, 286-293.	2.1	176
46	Exploring the relationship between white matter and gray matter damage in early primary progressive multiple sclerosis: An in vivo study with TBSS and VBM. Human Brain Mapping, 2009, 30, 2852-2861.	1.9	170
47	Quality of Life Measurement After Stroke. Stroke, 2002, 33, 1348-1356.	1.0	166
48	A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging. Journal of Neurology, 2003, 250, 287-292.	1.8	161
49	Regional Gray Matter Atrophy in Early Primary Progressive Multiple Sclerosis. Archives of Neurology, 2006, 63, 1175.	4.9	157
50	Clinical outcomes assessment in multiple sclerosis. Annals of Neurology, 1996, 40, 469-479.	2.8	155
51	Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis. Brain, 2007, 130, 2220-2231.	3.7	154
52	Optic nerve diffusion tensor imaging in optic neuritis. NeuroImage, 2006, 30, 498-505.	2.1	151
53	Characterizing functionâ€“structure relationships in the human visual system with functional MRI and diffusion tensor imaging. NeuroImage, 2004, 21, 1452-1463.	2.1	149
54	Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurology, The, 2010, 9, 1182-1199.	4.9	146

#	Article	IF	Citations
55	What sample sizes for reliability and validity studies in neurology?. Journal of Neurology, 2012, 259, 2681-2694.	1.8	140
56	Cell-based therapeutic strategies for multiple sclerosis. Brain, 2017, 140, 2776-2796.	3.7	139
57	Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study. Journal of Neurology, 2001, 248, 131-138.	1.8	136
58	The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology. Journal of Magnetic Resonance Imaging, 2002, 15, 259-267.	1.9	136
59	The relationship between brain activity and peak grip force is modulated by corticospinal system integrity after subcortical stroke. European Journal of Neuroscience, 2007, 25, 1865-1873.	1.2	136
60	Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. Brain, 2005, 128, 1454-1460.	3.7	135
61	Identifying brain regions for integrative sensorimotor processing with ankle movements. Experimental Brain Research, 2005, 166, 31-42.	0.7	132
62	Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. Lancet Neurology, The, 2005, 4, 341-348.	4.9	129
63	Neuroplasticity and functional recovery in multiple sclerosis. Nature Reviews Neurology, 2012, 8, 635-646.	4.9	128
64	Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 387-391.	1.4	125
65	A serial MRI study following optic nerve mean area in acute optic neuritis. Brain, 2004, 127, 2498-2505.	3.7	125
66	MRI in traumatic spinal cord injury: from clinical assessment to neuroimaging biomarkers. Lancet Neurology, The, 2019, 18, 1123-1135.	4.9	125
67	Traumatic and nontraumatic spinal cord injury: pathological insights from neuroimaging. Nature Reviews Neurology, 2019, 15, 718-731.	4.9	125
68	Investigation of white matter pathology in ALS and PLS using tractâ€based spatial statistics. Human Brain Mapping, 2009, 30, 615-624.	1.9	123
69	The influence of time after stroke on brain activations during a motor task. Annals of Neurology, 2004, 55, 829-834.	2.8	118
70	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Multiple Sclerosis Journal, 2016, 22, 1386-1396.	1.4	118
71	Diffusion tractography based group mapping of major white-matter pathways in the human brain. NeuroImage, 2003, 19, 1545-1555.	2.1	116
72	Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS. Multiple Sclerosis Journal, 2012, 18, 1534-1540.	1.4	116

#	Article	IF	Citations
73	Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain, 2003, 126, 2528-2536.	3.7	115
74	Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. Nature Reviews Neurology, 2018, 14, 75-93.	4.9	115
75	Optic radiation changes after optic neuritis detected by tractography-based group mapping. Human Brain Mapping, 2005, 25, 308-316.	1.9	114
76	Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. Nature Communications, 2021, 12, 2078.	5.8	112
77	The normal appearing grey matter in primary progressive multiple sclerosis. Journal of Neurology, 2003, 250, 67-74.	1.8	111
78	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197.	4.9	110
79	Serial magnetization transfer imaging in acute optic neuritis. Brain, 2003, 127, 692-700.	3.7	107
80	The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials, 2011, 12, 62.	0.7	104
81	Functional significance of the ipsilateral hemisphere during movement of the affected hand after stroke. Experimental Neurology, 2004, 190, 425-432.	2.0	103
82	Localization of grey matter atrophy in early RRMS. Journal of Neurology, 2006, 253, 1495-1501.	1.8	102
83	Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 844-850.	0.9	102
84	Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. Brain, 2005, 128, 2911-2925.	3.7	101
85	Predicting progression in primary progressive multiple sclerosis: A 10â€year multicenter study. Annals of Neurology, 2008, 63, 790-793.	2.8	101
86	Adaptive cortical plasticity in higher visual areas after acute optic neuritis. Annals of Neurology, 2005, 57, 622-633.	2.8	100
87	Correlates of Executive Function in Multiple Sclerosis:. Journal of Neuropsychiatry and Clinical Neurosciences, 1999, 11, 45-50.	0.9	99
88	A longitudinal study of cognition in primary progressive multiple sclerosis. Brain, 2005, 128, 2891-2898.	3.7	99
89	Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability. NeuroImage, 2007, 37, 253-261.	2.1	99
90	Factors influencing work retention for people with multiple sclerosis. Journal of Neurology, 2005, 252, 892-896.	1.8	98

#	Article	IF	Citations
91	Progressive neurodegeneration following spinal cord injury. Neurology, 2018, 90, e1257-e1266.	1.5	97
92	Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis. Brain, 2015, 138, 2584-2595.	3.7	95
93	Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis. Journal of Neurology, 2009, 256, 305-319.	1.8	94
94	Effects of a short outpatient rehabilitation treatment on disability of multiple sclerosis patients. Journal of Neurology, 2003, 250, 861-866.	1.8	91
95	Visual recovery following acute optic neuritis. Journal of Neurology, 2004, 251, 996-1005.	1.8	91
96	Selective magnetization transfer ratio decrease in the visual cortex following optic neuritis. Brain, 2006, 129, 1031-1039.	3.7	88
97	New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. Annals of Neurology, 2003, 53, 673-676.	2.8	85
98	Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities. Multiple Sclerosis Journal, 2003, 9, 566-573.	1.4	82
99	Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. NeuroImage, 2004, 22, 353-359.	2.1	80
100	MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain. Journal of Neurology, 2008, 255, 1-10.	1.8	80
101	Impact on Clinical and Cost Outcomes of a Centralized Approach to Acute Stroke Care in London: A Comparative Effectiveness Before and After Model. PLoS ONE, 2013, 8, e70420.	1.1	79
102	Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 833-839.	0.9	77
103	Tracking sensory system atrophy and outcome prediction in spinal cord injury. Annals of Neurology, 2015, 78, 751-761.	2.8	77
104	MRI measures show significant cerebellar gray matter volume loss in multiple sclerosis and are associated with cerebellar dysfunction. Multiple Sclerosis Journal, 2009, 15, 811-817.	1.4	76
105	Tracking Changes following Spinal Cord Injury. Neuroscientist, 2013, 19, 116-128.	2.6	76
106	Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multiâ€centre fMRI study. European Journal of Neurology, 2008, 15, 113-122.	1.7	75
107	Neuroplasticity predicts outcome of optic neuritis independent of tissue damage. Annals of Neurology, 2010, 67, 99-113.	2.8	75
108	Diffusion tensor imaging in early relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2001, 7, 290-297.	1.4	73

#	Article	IF	Citations
109	The 2013 clinical course descriptors for multiple sclerosis. Neurology, 2020, 94, 1088-1092.	1.5	73
110	Increasing normalâ€“appearing grey and white matter magnetisation transfer ratio abnormality in early relapsingâ€“remitting multiple sclerosis. Journal of Neurology, 2005, 252, 1037-1044.	1.8	72
111	Corticomotor representation to a human forearm muscle changes following cervical spinal cord injury. European Journal of Neuroscience, 2011, 34, 1839-1846.	1.2	72
112	A 1H magnetic resonance spectroscopy study of aging in parietal white matter: implications for trials in multiple sclerosis. Magnetic Resonance Imaging, 2000, 18, 455-459.	1.0	71
113	Normal-Appearing Brain T1 Relaxation Time Predicts Disability in Early Primary Progressive Multiple Sclerosis. Archives of Neurology, 2007, 64, 411.	4.9	71
114	Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. Journal of Neurology, 1997, 244, 76-84.	1.8	70
115	Imaging of the spinal cord and brain in multiple sclerosis: a comparative study between fast flair and fast spin echo. Journal of Neurology, 1997, 244, 119-124.	1.8	68
116	Metabolite changes in early relapsingâ€“remitting multiple sclerosis. Journal of Neurology, 2006, 253, 224-230.	1.8	68
117	Longitudinal evidence for anterograde trans-synaptic degeneration after optic neuritis. Brain, 2016, 139, 816-828.	3.7	67
118	A 30â€Year Clinical and Magnetic Resonance Imaging Observational Study of Multiple Sclerosis and Clinically Isolated Syndromes. Annals of Neurology, 2020, 87, 63-74.	2.8	67
119	Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis. Journal of Magnetic Resonance Imaging, 2003, 17, 389-397.	1.9	66
120	A three-year, multi-parametric MRI study in patients at presentation with CIS. Journal of Neurology, 2008, 255, 683-691.	1.8	65
121	Axonal integrity predicts cortical reorganisation following cervical injury. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 629-637.	0.9	65
122	The relationship between lesion and normal appearing brain tissue abnormalities in early relapsing remitting multiple sclerosis. Journal of Neurology, 2002, 249, 193-199.	1.8	64
123	Recommendations for observational studies of comorbidity in multiple sclerosis. Neurology, 2016, 86, 1446-1453.	1.5	64
124	Recovery after spinal cord relapse in multiple sclerosis is predicted by radial diffusivity. Multiple Sclerosis Journal, 2010, 16, 1193-1202.	1.4	63
125	Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest. Neurology, 2016, 87, 2463-2470.	1.5	63
126	Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis Journal, 2002, 8, 207-210.	1.4	62

#	Article	IF	Citations
127	Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 156-165.	1.4	62
128	A comprehensive assessment of cerebellar damage in multiple sclerosis using diffusion tractography and volumetric analysis. Multiple Sclerosis Journal, 2011, 17, 1079-1087.	1.4	62
129	Degeneration of the Injured Cervical Cord Is Associated with Remote Changes in Corticospinal Tract Integrity and Upper Limb Impairment. PLoS ONE, 2012, 7, e51729.	1.1	62
130	Predicting outcome in clinically isolated syndrome using machine learning. NeuroImage: Clinical, 2015, 7, 281-287.	1.4	61
131	Longitudinal Changes in Cerebral Response to Proprioceptive Input in Individual Patients after Stroke: An fMRI Study. Neurorehabilitation and Neural Repair, 2006, 20, 398-405.	1.4	60
132	Magnetization Transfer Ratio in Gray Matter. Archives of Neurology, 2008, 65, 1454.	4.9	59
133	Functional response to active and passive ankle movements with clinical correlations in patients with primary progressive multiple sclerosis. Journal of Neurology, 2006, 253, 882-891.	1.8	58
134	Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 455-464.	1.4	58
135	Two-dimensional population map of cortical connections in the human internal capsule. Journal of Magnetic Resonance Imaging, 2007, 25, 48-54.	1.9	56
136	Does neurorehabilitation have a role in relapsing-remitting multiple sclerosis?. Journal of Neurology, 2003, 250, 1214-1218.	1.8	53
137	Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition. Experimental Brain Research, 2008, 187, 25-31.	0.7	52
138	Hippocampal atrophy in relapsing-remitting and primary progressive MS: a comparative study. Multiple Sclerosis Journal, 2010, 16, 1083-1090.	1.4	52
139	Voxel-based analysis of grey and white matter degeneration in cervical spondylotic myelopathy. Scientific Reports, 2016, 6, 24636.	1.6	52
140	Abnormal connectivity of the sensorimotor network in patients with MS: A multicenter fMRI study. Human Brain Mapping, 2009, 30, 2412-2425.	1.9	51
141	Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis. Brain, 2015, 138, 1568-1582.	3.7	51
142	Macroscopic and microscopic assessments of disease burden by MRI in multiple sclerosis: Relationship to clinical parameters. Journal of Magnetic Resonance Imaging, 1996, 6, 580-584.	1.9	50
143	Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis. Multiple Sclerosis Journal, 2004, 10, S2-S7.	1.4	50
144	Reproducibility of fMRI in the clinical setting: Implications for trial designs. NeuroImage, 2008, 42, 603-610.	2.1	49

#	Article	IF	Citations
145	Symptomatic treatment and management of multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 513-562.	1.0	49
146	Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta. Multiple Sclerosis Journal, 2008, 14, 212-218.	1.4	48
147	The challenge of comorbidity in clinical trials for multiple sclerosis. Neurology, 2016, 86, 1437-1445.	1.5	48
148	Reduced neurite density in the brain and cervical spinal cord in relapsingâ€“remitting multiple sclerosis: A NODDI study. Multiple Sclerosis Journal, 2020, 26, 1647-1657.	1.4	48
149	Optic nerve magnetization transfer imaging and measures of axonal loss and demyelination in optic neuritis. Multiple Sclerosis Journal, 2007, 13, 875-879.	1.4	47
150	Assessing Neuronal Metabolism In Vivo by Modeling Imaging Measures. Journal of Neuroscience, 2010, 30, 15030-15033.	1.7	47
151	Muscle paresis and passive stiffness: Key determinants in limiting function in Hereditary and Sporadic Spastic Paraparesis. Gait and Posture, 2012, 35, 266-271.	0.6	46
152	Quantitative MRI of rostral spinal cord and brain regions is predictive of functional recovery in acute spinal cord injury. NeuroImage: Clinical, 2018, 20, 556-563.	1.4	46
153	Estimation of the macromolecular proton fraction and bound pool T2 in multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 607-613.	1.4	45
154	Diffusion tensor imaging of early relapsing-remitting multiple sclerosis with histogram analysis using automated segmentation and brain volume correction. Multiple Sclerosis Journal, 2004, 10, 9-15.	1.4	45
155	Corpus callosum damage predicts disability progression and cognitive dysfunction in primaryâ€progressive MS after five years. Human Brain Mapping, 2013, 34, 1163-1172.	1.9	45
156	Upper cervical cord area in early relapsing-remitting multiple sclerosis: Cross-sectional study of factors influencing cord size. Journal of Magnetic Resonance Imaging, 2006, 23, 473-476.	1.9	44
157	Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 483-489.	1.4	44
158	Low Myoâ€inositol indicating astrocytic damage in a case series of neuromyelitis optica. Annals of Neurology, 2013, 74, 301-305.	2.8	44
159	Temporal and spatial evolution of grey matter atrophy in primary progressive multiple sclerosis. NeuroImage, 2014, 86, 257-264.	2.1	44
160	Dorsal and ventral horn atrophy is associated with clinical outcome after spinal cord injury. Neurology, 2018, 90, e1510-e1522.	1.5	44
161	Two-year follow-up study of primary and transitional progressive multiple sclerosis. Multiple Sclerosis Journal, 2002, 8, 108-114.	1.4	43
162	Effect sizes can be misleading: is it time to change the way we measure change?. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1044-1048.	0.9	43

#	Article	IF	Citations
163	Primary Progressive Multiple Sclerosis. CNS Drugs, 2005, 19, 369-376.	2.7	41
164	Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial. Lancet Neurology, The, 2006, 5, 565-571.	4.9	41
165	Normal-appearing grey and white matter T1 abnormality in early relapsingâ€“remitting multiple sclerosis: a longitudinal study. Multiple Sclerosis Journal, 2007, 13, 169-177.	1.4	41
166	Developing the ICF Core Sets for multiple sclerosis to specify functioning. Multiple Sclerosis Journal, 2008, 14, 252-254.	1.4	41
167	Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 668-677.	1.4	41
168	European validation of a standardized clinical description of multiple sclerosis. Journal of Neurology, 2004, 251, 1472-1480.	1.8	40
169	Embodied neurology: an integrative framework for neurological disorders. Brain, 2016, 139, 1855-1861.	3.7	39
170	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Multiple Sclerosis Journal, 2020, 26, 1031-1044.	1.4	39
171	Patient-based outcomes of cervical dystonia: A review of rating scales. Movement Disorders, 2004, 19, 1054-1059.	2.2	38
172	DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 461-467.	0.9	38
173	Patterns of disease activity in multiple sclerosis patients: A study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups. Journal of Neurology, 1996, 243, 536-542.	1.8	37
174	Exploring rating scale responsiveness. Neurology, 2004, 62, 1842-1844.	1.5	37
175	Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 932-941.	1.4	37
176	Structural network disruption markers explain disability in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 219-226.	0.9	37
177	T1 histograms of normal-appearing brain tissue are abnormal in early relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2002, 8, 211-216.	1.4	36
178	Disability and lesion load in MS: a reassessment with MS functional composite score and 3D fast FLAIR. Journal of Neurology, 2002, 249, 18-24.	1.8	36
179	Emergence of thalamic magnetization transfer ratio abnormality in early relapsingâ€”remitting multiple sclerosis. Multiple Sclerosis Journal, 2005, 11, 276-281.	1.4	35
180	Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis. Clinical Neurology and Neurosurgery, 2006, 108, 456-460.	0.6	35

#	Article	IF	Citations
181	Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. Multiple Sclerosis Journal, 2009, 15, 1459-1465.	1.4	35
182	Changes in Auditory Feedback Connections Determine the Severity of Speech Processing Deficits after Stroke. Journal of Neuroscience, 2012, 32, 4260-4270.	1.7	35
183	Progressive MS: from pathophysiology to drug discovery. Multiple Sclerosis Journal, 2015, 21, 1376-1384.	1.4	35
184	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis â€“ Authors' reply. Lancet Neurology, The, 2018, 17, 499-500.	4.9	35
185	Dissecting structureâ€“function interactions in acute optic neuritis to investigate neuroplasticity. Human Brain Mapping, 2010, 31, 276-286.	1.9	34
186	White and gray matter damage in primary progressive MS. Neurology, 2016, 86, 170-176.	1.5	34
187	Method for simultaneous voxelâ€based morphometry of the brain and cervical spinal cord area measurements using 3Dâ€MDEFT. Journal of Magnetic Resonance Imaging, 2010, 32, 1242-1247.	1.9	33
188	Combining tractography and cortical measures to test system-specific hypotheses in multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 555-565.	1.4	33
189	Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 322-328.	1.4	33
190	Preliminary magnetic resonance study of the macromolecular proton fraction in white matter: a potential marker of myelin?. Multiple Sclerosis Journal, 2003, 9, 246-249.	1.4	32
191	Specificity of Barkhof Criteria in Predicting Conversion to Multiple Sclerosis When Applied to Clinically Isolated Brainstem Syndromes. Archives of Neurology, 2004, 61, 222.	4.9	32
192	Achieving valid patient-reported outcomes measurement: a lesson from fatigue in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1773-1783.	1.4	32
193	Control of spasticity in a multiple sclerosis model using central nervous systemâ€excluded CB ₁ cannabinoid receptor agonists. FASEB Journal, 2014, 28, 117-130.	0.2	32
194	Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy. Journal of Neurology, 2002, 249, 171-177.	1.8	31
195	Lesion enhancement diminishes with time in primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 317-324.	1.4	31
196	Introduction of integrated care pathways for patients with multiple sclerosis in an inpatient neurorehabilitation setting. Disability and Rehabilitation, 1995, 17, 443-448.	0.9	30
197	Neurorehabilitation in multiple sclerosis: foundations, facts and fiction. Current Opinion in Neurology, 2005, 18, 267-271.	1.8	30
198	A much-needed focus on progression in multiple sclerosis. Lancet Neurology, The, 2015, 14, 133-135.	4.9	30

#	Article	IF	Citations
199	White matter tract abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1429-1437.	1.4	30
200	TI-relaxation time changes over five years in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 427-433.	1.4	28
201	Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11020-11027.	3.3	28
202	Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort. Multiple Sclerosis Journal, 2020, 26, 1372-1380.	1.4	28
203	Pathologic correlates of the magnetization transfer ratio in multiple sclerosis. Neurology, 2020, 95, e2965-e2976.	1.5	28
204	Longitudinal evaluation of clinically early relapsing-remitting multiple sclerosis with diffusion tensor imaging. Journal of Neurology, 2008, 255, 390-397.	1.8	27
205	Magnetic resonance imaging predictors of disability in primary progressive multiple sclerosis: a 5-year study. Multiple Sclerosis Journal, 2004, 10, 398-401.	1.4	25
206	Quantification of optic nerve head topography in optic neuritis: a pilot study. British Journal of Ophthalmology, 2006, 90, 1128-1131.	2.1	25
207	Voxel-based cervical spinal cord mapping of diffusion abnormalities in MS-related myelitis. Neurology, 2014, 83, 1321-1325.	1.5	24
208	New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom. Multiple Sclerosis Journal, 2017, 23, 204-216.	1.4	24
209	Landscape of MS patient cohorts and registries: Recommendations for maximizing impact. Multiple Sclerosis Journal, 2018, 24, 579-586.	1.4	24
210	Cortical involvement determines impairment 30 years after a clinically isolated syndrome. Brain, 2021, 144, 1384-1395.	3.7	24
211	Application of a B-spline active surface technique to the measurement of cervical cord volume in multiple sclerosis from three-dimensional MR images. Journal of Magnetic Resonance Imaging, 2003, 18, 368-371.	1.9	23
212	The distribution of magnetic resonance imaging response to interferonÎ²â€“1b in multiple sclerosis. Journal of Neurology, 2005, 252, 1455-1458.	1.8	23
213	Aggressive multiple sclerosis (2): Treatment. Multiple Sclerosis Journal, 2020, 26, 1045-1063.	1.4	21
214	Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1473-1476.	1.4	21
215	Urinary neopterin and nitric oxide metabolites as markers of interferon Î²-1a activity in primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 1066-1072.	1.4	20
216	Challenge of progressive multiple sclerosis therapy. Current Opinion in Neurology, 2017, 30, 237-240.	1.8	20

#	Article	IF	Citations
217	Longitudinal changes of spinal cord grey and white matter following spinal cord injury. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1222-1230.	0.9	20
218	The predictive value of gadolinium enhancement for long term disability in relapsingâ€“remitting multiple sclerosis â€“ preliminary results. Multiple Sclerosis Journal, 2001, 7, 23-25.	1.4	20
219	The Cervical Dystonia Impact Profile (CDIP-58): Can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria?. Health and Quality of Life Outcomes, 2008, 6, 58.	1.0	19
220	Evidence-based guidelines for using the Short Form 36 in cervical dystonia. Movement Disorders, 2007, 22, 122-127.	2.2	18
221	Metabolic Changes in the Spinal Cord After Brachial Plexus Root Re-implantation. Neurorehabilitation and Neural Repair, 2013, 27, 118-124.	1.4	18
222	HLA-DRB1*15 influences the development of brain tissue damage in early PPMS. Neurology, 2014, 83, 1712-1718.	1.5	18
223	Atlas of MS 2020: Informing global policy change. Multiple Sclerosis Journal, 2020, 26, 1807-1808.	1.4	18
224	Linking white matter tracts to associated cortical grey matter: A tract extension methodology. NeuroImage, 2012, 59, 3094-3102.	2.1	17
225	Adolescent and Adult Children of Parents with Parkinson's Disease: Incorporating Their Needs in Clinical Guidelines. Parkinson's Disease, 2011, 2011, 1-6.	0.6	16
226	Age Related Changes in Metabolite Concentrations in the Normal Spinal Cord. PLoS ONE, 2014, 9, e105774.	1.1	16
227	Rehabilitation of the Cancer Patient: Experience in a Neurological Unit. Neurorehabilitation and Neural Repair, 2004, 18, 76-79.	1.4	15
228	Towards treating progressive multiple sclerosis. Nature Reviews Neurology, 2020, 16, 589-590.	4.9	15
229	Rehabilitation in a neuroscience centre: the role of expert assessment and selection. International Journal of Therapy and Rehabilitation, 1996, 3, 303-308.	0.1	14
230	Progress in neurorehabilitation in multiple sclerosis. Current Opinion in Neurology, 2002, 15, 267-270.	1.8	14
231	Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a. Journal of Neurology, 2003, 250, 1037-1043.	1.8	14
232	Clinical relevance of cortical network dynamics in early primary progressive MS. Multiple Sclerosis Journal, 2020, 26, 442-456.	1.4	14
233	Refinement and validation of the Parental Illness Impact Scale. Parkinsonism and Related Disorders, 2010, 16, 181-185.	1.1	12
234	A novel approach with â€œskeletonised MTRâ€•measures tractâ€specific microstructural changes in early primaryâ€progressive MS. Human Brain Mapping, 2014, 35, 723-733.	1.9	12

#	Article	IF	Citations
235	Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study. Multiple Sclerosis Journal, 2007, 13, 178-185.	1.4	11
236	The patient's experience of being a human subject. Journal of the Royal Society of Medicine, 2008, 101, 416-422.	1.1	11
237	Asymmetric hemispheric representation of periictal heart rate modulation is individually lateralised. Epileptic Disorders, 2011, 13, 172-176.	0.7	11
238	Spatial variability and changes of metabolite concentrations in the corticoâ€spinal tract in multiple sclerosis using coronal CSI. Human Brain Mapping, 2014, 35, 993-1003.	1.9	11
239	Unified understanding of MS course is required for drug development. Nature Reviews Neurology, 2018, 14, 191-192.	4.9	11
240	Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 28-38.	1.4	11
241	Improving function: a new treatment era for multiple sclerosis?. Lancet, The, 2009, 373, 697-698.	6.3	10
242	Socio-demographic variables are limited predictors of health status in multiple sclerosis. Journal of Neurology, 2003, 250, 1088-1093.	1.8	9
243	Scanning Laser Polarimetry Quantification of Retinal Nerve Fiber Layer Thinning Following Optic Neuritis. Journal of Neuro-Ophthalmology, 2010, 30, 235-242.	0.4	9
244	Integrated care pathways: evaluating inpatient rehabilitation in stroke. International Journal of Therapy and Rehabilitation, 1997, 4, 97-102.	0.1	8
245	Developing clinical outcome measures in multiple sclerosis: an evolving process. Multiple Sclerosis Journal, 2002, 8, 357-358.	1.4	8
246	Is multiple sclerosis still a clinical diagnosis?. Neurology, 2003, 61, 596-597.	1.5	8
247	Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis. Journal of Neuroimmunology, 2010, 220, 99-103.	1.1	8
248	A longitudinal functional MRI study of non-arteritic anterior ischaemic optic neuropathy patients. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 905-913.	0.9	8
249	Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis. Philosophical Transactions of the Royal Society B: Biological Sciences, 1999, 354, 1687-1695.	1.8	7
250	Patient dissatisfaction: Insights into the rehabilitation process. Journal of Neurology, 2004, 251, 1094-7.	1.8	7
251	The impact of inpatient neurorehabilitation on psychological wellâ€"being on discharge and at 3 month followâ€"up. Journal of Neurology, 2005, 252, 814-819.	1.8	7
252	Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years. BMC Neurology, 2008, 8, 2.	0.8	7

#	Article	IF	Citations
253	The size of the treatment effect: do patients and proxies agree?. BMC Neurology, 2009, 9, 12.	0.8	7
254	When are we going to take modifiable risk factors more seriously in multiple sclerosis?. Multiple Sclerosis Journal, 2017, 23, 494-495.	1.4	7
255	Author response: Progressive neurodegeneration following spinal cord injury: Implications for clinical trials. Neurology, 2018, 91, 985-985.	1.5	7
256	Promises, promisesâ€¦. Annals of Neurology, 2007, 61, 1-2.	2.8	6
257	Atopic myelitis in a European woman residing in Japan. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1022-1024.	0.9	6
258	A Predictive Model for Corticosteroid Response in Individual Patients with MS Relapses. PLoS ONE, 2015, 10, e0120829.	1.1	6
259	Editorial. Multiple Sclerosis Journal, 2017, 23, 2-3.	1.4	6
260	Multiple Sclerosis and Demyelinating Diseases. , 0, , 411-447.		5
261	Chronic cerebrospinal venous insufficiency. Multiple Sclerosis Journal, 2010, 16, 770-770.	1.4	5
262	Connecting to the future â€“ the promise of telecare. Multiple Sclerosis Journal, 2012, 18, 384-386.	1.4	5
263	The measure tells the tale: Clinical outcome measures in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 626-627.	1.4	5
264	Advancing trial design in progressive multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1571-1572.	1.4	5
265	Primary progressive multiple sclerosis presenting under the age of 18 years: Fact or fiction?. Multiple Sclerosis Journal, 2021, 27, 309-314.	1.4	5
266	Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study. Multiple Sclerosis Journal, 2001, 7, 75-82.	1.4	5
267	Spatial patterns of brain lesions assessed through covariance estimations of lesional voxels in multiple Sclerosis: The SPACE-MS technique. NeuroImage: Clinical, 2022, 33, 102904.	1.4	5
268	Charting a global research strategy for progressive MSâ€”An international progressive MS Alliance proposal. Multiple Sclerosis Journal, 2022, 28, 16-28.	1.4	5
269	Simultaneous assessment of regional distributions of atrophy across the neuraxis in MS patients. NeuroImage: Clinical, 2022, 34, 102985.	1.4	5
270	Management of spasticity in hereditary spastic paraplegia. Physiotherapy Research International, 1999, 4, 68-76.	0.7	4

#	Article	IF	Citations
271	A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS). Health and Quality of Life Outcomes, 2011, 9, 80.	1.0	4
272	A little bit of toxin does you good?. Physiotherapy Research International, 1996, 1, 141-147.	0.7	3
273	Evaluating the role of botulinum toxin type A in adults with focal spasticity. European Journal of Neurology, 1999, 6, s75-s75.	1.7	3
274	Multiple Sclerosis International Federation: Stimulating international cooperation in research. Neurology, 2013, 81, 1793-1795.	1.5	3
275	Two years of COVID-19 in the MS community: What have we learnt so far?. Multiple Sclerosis Journal, 2022, 28, 1005-1008.	1.4	3
276	Removal of access to alemtuzumab for patients with aggressive multiple sclerosis. BMJ, The, 2013, 346, f275-f275.	3.0	2
277	Multiple sclerosis: the upward trajectory continues. Lancet Neurology, The, 2017, 16, 10-12.	4.9	2
278	Commentary on the ECTRIMSâ€“EAN guideline for pharmacological treatment of multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641877037.	1.5	2
279	Disrupted principal network organisation in multiple sclerosis relates to disability. Scientific Reports, 2020, 10, 3620.	1.6	2
280	Chapter 1 The Diagnosis of Multiple Sclerosis. Blue Books of Practical Neurology, 2003, 27, 1-11.	0.1	1
281	The physiopathology of multiple sclerosis. , 0, , 8-21.		1
282	MSJ 2018â€”editorial comment. Multiple Sclerosis Journal, 2018, 24, 90-91.	1.4	1
283	Clinical trials to test rehabilitation. , 0, , 157-164.		1
284	The diagnosis and management of multiple sclerosis. , 2002, , 1620-1632.		0
285	Chapter 22 Treatment of Progressive Multiple Sclerosis. Blue Books of Practical Neurology, 2003, 27, 341-359.	0.1	0
286	Chapter 20 Rehabilitation in Multiple Sclerosis. Blue Books of Practical Neurology, 2003, 27, 317-328.	0.1	0
287	Value and limits of rehabilitation in multiple sclerosis. , 0, , 140-151.		0
288	Electrophysiological assessment in multiple sclerosis. , 0, , 112-119.		0

#	Article	IF	Citations
289	Treatment for patients with primary progressive multiple sclerosis. , 0, , 604-613.		0
290	SPINAL CORD GLUTAMATE-GLUTAMINE IS ELEVATED IN MS RELAPSE. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.30-e4.	0.9	0
291	Editorial 2016. Multiple Sclerosis Journal, 2016, 22, 4-4.	1.4	0
292	Editorial 2017. Multiple Sclerosis Journal, 2017, 23, 4-4.	1.4	0
293	2018 Editorsâ€™ commentary. Multiple Sclerosis Journal, 2018, 24, 1394-1395.	1.4	0
294	MSJ 2019 - Editorial comment. Multiple Sclerosis Journal, 2019, 25, 4-5.	1.4	0
295	Brenda Banwell. , 2021, , 609-611.		0
296	Neurorehabilitation in Multiple Sclerosis. Topics in Spinal Cord Injury Rehabilitation, 2008, 14, 63-75.	0.8	0
297	Magnetic resonance imaging to assess gray matter damage in multiple sclerosis. , 0, , 86-92.		0
298	Application of functional magnetic resonance imaging in multiple sclerosis. , 0, , 93-102.		0
299	Functional magnetic resonance imaging in focal CNS damage. , 0, , 103-111.		0
300	Functional magnetic resonance imaging monitoring of therapeutic interventions in multiple sclerosis. , 0, , 120-126.		0
301	Prognosis in neurorehabilitation. , 0, , 152-156.		0
302	Back home. , 0, , 230-239.		0